These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16455169)

  • 1. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine.
    Rendi-Wagner P; Shouval D; Genton B; Lurie Y; Rümke H; Boland G; Cerny A; Heim M; Bach D; Schroeder M; Kollaritsch H
    Vaccine; 2006 Apr; 24(15):2781-9. PubMed ID: 16455169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B vaccine.
    Madaliński K; Sylvan SP; Hellstrom U; Mikołajewicz J; Dzierzanowska-Fangrat K
    Med Sci Monit; 2004 Jan; 10(1):PI10-7. PubMed ID: 14704645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
    Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
    Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
    Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
    Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
    Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine.
    Sylvan SP; Madalinski K; Hellström UB
    Vaccine; 2009 Dec; 28(2):446-51. PubMed ID: 19874926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.
    Leroux-Roels G; Desombere I; Cobbaut L; Petit MA; Desmons P; Hauser P; Delem A; De Grave D; Safary A
    Vaccine; 1997 Nov; 15(16):1732-6. PubMed ID: 9364675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
    Jafarzadeh A; Zarei S; Shokri F
    Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Simultaneous expression of modified hepatitis B surface antigen fusion polypeptides containing preS1, preS2 epitopes in Pichia pastoris].
    Tan CY; Jiang LM; Ge YH; Yuan J; Jin O; Hu B
    Sheng Wu Gong Cheng Xue Bao; 2006 Jul; 22(4):604-8. PubMed ID: 16894895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Humoral immunological response in laboratory animals after vaccination with recombinant vaccines against viral hepatitis B of different generations].
    Górska P
    Przegl Epidemiol; 2007; 61(2):393-400. PubMed ID: 17956059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
    Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults.
    Eyigün CP; Yilmaz S; Gül C; Sengül A; Hacibektasoglu A; Van Thiel DH
    J Viral Hepat; 1998 Jul; 5(4):265-9. PubMed ID: 9751013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Persistence of immunity after hepatitis B vaccination].
    Madaliński K
    Przegl Epidemiol; 2002; 56(4):605-13. PubMed ID: 12666586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth.
    Carniel EF; Morcillo AM; Blotta MH; Da Silva MT; Mazzola TN; Antonio MA; Zanolli ML; Netto AA; Higashi HG; Raw I; Vilela MM
    Vaccine; 2008 Jan; 26(5):647-52. PubMed ID: 18155811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site.
    Cupps TR; Tibbles J; Hurni WM; Miller WJ; Ellis RW; Milich D; Wetter N
    J Immunol; 1993 Sep; 151(6):3353-60. PubMed ID: 7690803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.